Noliterax (Indapamide, Perindopril Arginine)

Noliterax is an antihypertensive medication that works within the renin‑angiotensin‑aldosterone system and renal sodium handling pathways.

• Hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension.
• Heart failure: assists in blood‑pressure control as part of a physician‑directed regimen for patients with heart failure.
• Diabetic nephropathy: helps achieve target blood pressure in patients with diabetes, supporting renal protection.

• Indapamide blocks NaCl reabsorption in the distal renal tubule, promoting diuresis and reducing plasma volume. Perindopril inhibits angiotensin‑converting enzyme, decreasing formation of angiotensin II and thereby reducing vasoconstriction and aldosterone secretion. The combined actions lower systemic vascular resistance and blood pressure.

Noliterax may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Persistent dry cough
• Increased urinary frequency
• Electrolyte disturbances (e.g., low potassium)
• Fatigue or weakness

Serious or Rare Side Effects

• Severe hypotension
• Angioedema (swelling of face, lips, tongue)
• Hyperkalemia
• Acute renal impairment
• Pancreatitis
• Blood dyscrasias such as agranulocytosis

Before initiating Noliterax, several safety considerations should be observed.

• Blood pressure monitoring: ensure adequate control and avoid excessive drops.
• Renal function assessment: evaluate serum creatinine and eGFR prior to use.
• Electrolyte checks: monitor potassium and sodium levels regularly.
• Contraindication in severe renal impairment: avoid if eGFR is markedly reduced.
• Caution with potassium‑sparing agents: risk of hyperkalemia.
• Allergy to ACE inhibitors: discontinue if angioedema occurs.
• Store at ambient temperature: keep in the original container, protect from moisture.

Noliterax can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Aliskiren in diabetic patients: increased risk of renal dysfunction.
• Potassium supplements or high‑potassium diet: may cause hyperkalemia.
• NSAIDs (e.g., ibuprofen, naproxen): can diminish antihypertensive effect and impair renal function.
• Lithium: risk of lithium toxicity due to reduced clearance.
• Other potent diuretics: may lead to severe electrolyte imbalance.

Moderate Interactions (Monitor Closely)

• ARBs or other ACE inhibitors: additive blood‑pressure lowering effect.
• Beta‑blockers: may enhance hypotensive response.
• Thiazide diuretics: monitor electrolytes closely.
• Certain antibiotics (e.g., trimethoprim‑sulfamethoxazole): can increase potassium levels.
• Glucocorticoids: may counteract antihypertensive effect.